Skip to main content

Table 2 SARAH trial assessment schedule

From: Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial

Visits

Enrolment/randomisation

D0

D15

M1

M2

M3

M4

M5

M6

M7

M8

M9

End of participation

Identification

X

            

Verification of selection criteria

X

            

Consent signature

X

            

Initial assessment – history

X

            

CT scan

X

  

X

 

X

  

X

  

X

X

CT perfusion

X

  

X

 

X

  

X

    

Laboratory tests

X

X

X

X

X

X

X

X

X

X

X

X

X

Classification

X

  

X

X

X

X

X

X

X

X

X

X

Clinical examination

   

X

X

X

X

X

X

X

X

X

X

Quality of life questionnaires

X

  

X

 

X

  

X

  

X

X

Preparatory angiography

 

X

           

Scintigraphy

 

X

           

RE

 

X

           

Start of sorafenib treatment

 

X

           

Retreatment*

   

X

X

X

X

X

X

X

X

X

 

Cancer progression monitoring

   

X

X

X

X

X

X

X

X

X

X

Sorafenib monitoring

   

X

X

X

X

X

X

X

X

X

X

Concomitant medication

   

X

X

X

X

X

X

X

X

X

X

Adverse events

   

X

X

X

X

X

X

X

X

X

X

  1. *Timing of retreatment depends upon type of retreatment (see text). CT, computed tomography; D, day; M, month; RE, radioembolisation.